These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36136811)

  • 1. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
    Hermans LE; Umunnakwe CN; Lalla-Edward ST; Hebel SK; Tempelman HA; Nijhuis M; Venter WDF; Wensing AMJ
    Clin Infect Dis; 2023 Feb; 76(3):e553-e560. PubMed ID: 36136811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
    McCluskey SM; Govender K; Adamson J; Gandhi M; Spinelli MA; Moosa MY; Muyindike W; Moodley P; Pillay M; Masette G; Sunpath H; Pillay S; Chen G; Hedt-Gauthier B; Marconi VC; Siedner MJ
    AIDS; 2023 Jun; 37(7):1109-1113. PubMed ID: 36928169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
    Dorward J; Lessells R; Govender K; Moodley P; Samsunder N; Sookrajh Y; Turner P; Butler CC; Hayward G; Gandhi M; Drain PK; Garrett N
    J Int AIDS Soc; 2023 Sep; 26(9):e26172. PubMed ID: 37735860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
    Jennings L; Kellermann T; Spinelli M; Nkantsu Z; Cogill D; van Schalkwyk M; Decloedt E; van Zyl G; Orrell C; Gandhi M
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):455-462. PubMed ID: 34779228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
    Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
    BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
    Marryshow TA; Muhairwe J; Tang A; Molulela MMM; Matta R; Jordan MR
    Int J STD AIDS; 2022 Jul; 33(8):777-783. PubMed ID: 35611960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
    Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
    AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
    Drain PK; Kubiak RW; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Sukrakanchana PO; Tanasri S; Punyati P; Sirirungsi W; Cressey R; Bacchetti P; Okochi H; Baeten JM; Gandhi M; Cressey TR
    Clin Infect Dis; 2020 May; 70(10):2143-2151. PubMed ID: 31314073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy.
    Dorward J; Govender K; Moodley P; Lessells R; Samsunder N; Sookrajh Y; Fanshawe TR; Turner PJ; Butler CC; Drain PK; Hayward GN; Garrett N
    AIDS; 2024 Apr; 38(5):697-702. PubMed ID: 38126342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing a point-of-care urine tenofovir lateral flow assay to self-reported adherence and their associations with viral load suppression among adults on antiretroviral therapy.
    Phillips T; Gomba Y; Myer L
    Trop Med Int Health; 2024 Feb; 29(2):96-103. PubMed ID: 38084797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
    Singh Y; Castillo-Mancilla J; Madimabe R; Jennings L; Ferraris CM; Robbins RN; Anderson PL; Remien RH; Orrell C
    AIDS Res Ther; 2023 Sep; 20(1):67. PubMed ID: 37705102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    van Heerden JK; Meintjes G; Barr D; Zhao Y; Griesel R; Keene CM; Wiesner L; Galileya LT; Denti P; Maartens G
    J Acquir Immune Defic Syndr; 2024 Mar; 95(3):260-267. PubMed ID: 38408216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study.
    Castillo-Mancilla JR; Edwards JA; Brijkumar J; Moosa MY; Zhao Y; Ofotokun I; Johnson BA; Lee MH; Pillay S; Pillay M; Moodley P; Kuritzkes DR; Sunpath H; Bushman LR; Ellison L; Anderson PL; Marconi VC
    J Int AIDS Soc; 2021 Dec; 24(12):e25849. PubMed ID: 34910844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.